Mediwound (MDWD)
NASDAQ:MDWD
Want to see MDWD full AI Analyst Report?
MDWD Stock Chart & Stats
$16.40
-$0.64(-3.70%)
At close: 4:00 PM EST
$16.40
-$0.64(-3.70%)
Day’s Range― - ―
52-Week Range$13.54 - $21.32
Previous CloseN/A
Volume29.05K
Average Volume (3M)83.89K
Market Cap
$178.04M
Enterprise Value$119.14M
Total Cash (Recent Filing)$44.65M
Total Debt (Recent Filing)$8.13M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 19, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.26
Shares Outstanding12,845,664
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.81
Price to Sales (P/S)12.38
P/FCF Ratio-10.48
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue8.23
Enterprise Value/Gross Profit41.97
Enterprise Value/Ebitda-4.92
Forecast
1Y Price Target
$29.00Price Target Upside76.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$24.20M
Bulls Say, Bears Say
Bulls Say
Government Contract (BARDA)A decade‑long BARDA contract provides a durable, government‑backed revenue stream, supporting predictable procurement and stockpile buys. This reduces reliance on volatile commercial demand, underpins scale-up economics, and improves visibility for multi-year manufacturing and development planning.
Manufacturing Capacity ExpansionA sixfold boost to manufacturing capacity materially strengthens supply capability to meet BARDA and commercial demand, enabling scale economies and improved margin potential. Greater in‑house capacity also reduces partner dependence and supports lifecycle extensions and formulation development.
Strategic Collaborations For EscharExBroad partnerships with major wound‑care players enhance trial execution, distribution options and clinical credibility. These alliances de‑risk commercialization pathways, accelerate trial enrollment support and increase the chance of adoption across hospital and outpatient channels long term.
Bears Say
Sustained Cash BurnMeaningful negative operating and free cash flow signal ongoing reliance on external financing to fund R&D and operations. Continued high burn reduces runway, raises dilution risk if capital markets tighten, and constrains strategic optionality for commercialization or M&A over the next several quarters.
Declining Revenue & Weak ProfitabilityA falling revenue trend and large recurring losses with low gross margins indicate limited operating leverage and unstable demand. Without sustained top‑line growth or margin expansion, the company will struggle to absorb higher R&D and SG&A, delaying a durable path to profitability.
Execution And Regulatory RisksRequired facility changes, pending inspections and trial enrollment delays create timing risk for revenue realization and regulatory approvals. Execution slippage can push back BARDA procurement and clinical milestones, raising near‑term cost and reimbursement uncertainty and elongating commercialization timelines.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $13.54 and its highest was $21.32 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $178.04M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Aug 19, 2026 which is in 69 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on May 27, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.653 by $0.423.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.76.
How many shares outstanding does Mediwound have?
Mediwound has 12,845,664 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.653. Following the earnings report the stock price went down -14.089%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (76.83% Upside)
$29.00 (76.83% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 23.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $136.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.91%
12-Months-Change
Fundamentals
Return on Equity
-67.22%
Trailing 12-Months
Asset Growth
15.89%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., an Israeli biopharmaceutical company established in 2000 and based in Yavne, focuses on the innovation, production, and sale of advanced biological treatments for the healing and regrowth of damaged tissues. The company's key commercialized product is NexoBrid, a biological drug distributed to specialized burn centers and hospital burn units. NexoBrid is specifically formulated for the enzymatic debridement of eschar—dead or compromised tissue—in adults suffering from severe thermal burns, encompassing deep partial-thickness and full-thickness injuries. Furthermore, MediWound's development pipeline includes EscharEx, which has successfully concluded Phase II clinical trials for addressing chronic and other intractable wounds. Another investigational therapy, MW005, is currently undergoing Phase I/II clinical studies for the treatment of low-risk basal cell carcinoma.
MDWD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of positive strategic progress (clinical advancement for EscharEx, broad industry collaborations, strong government backing for NexoBrid via BARDA, and improved gross margin) alongside notable near-term financial and operational challenges (sharp Q1 revenue decline, higher R&D and losses, enrollment pacing issues, regulatory/ manufacturing implementation work, and reimbursement headwinds). Management reaffirmed full-year revenue guidance and outlined specific remediation steps (patient assistance, EMA actions), but near-term execution and cash consumption remain areas to watch.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$29.00
▲(76.83% Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
―
Tevogen Bio Holdings
―
Ownership Overview
0.66% Insiders
5.66% Mutual Funds
28.88% Other Institutional Investors
60.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---